Patent Application
20240288437
The present disclosure provides systems and methods for the prediction and treatment of recurrent cancer in a subject. Provided herein is the analysis of subcellular localization of phosphofructokinase type L (PFKL), phosphofructokinase/fructose-2,6-bisphosphatase type 4 (PFKFB4), and other biomarkers, and correlation thereof to the likelihood of cancer (e.g., DCIS) recurrence.
Ductal carcinoma in situ (DCIS) of the breast is a common non-invasive cancer. Epidemiology studies suggest that indolent and aggressive forms of DCIS exist, with the aggressive form potentially leading to life-threatening disease. The two presumed forms of DCIS would exhibit cellular proliferation (indolent) or cellular proliferation plus biochemical and biophysical changes to support invasive behavior (aggressive). Some patients treated for ductal carcinoma in situ (DCIS) of the breast will experience cancer recurrences, whereas other patients will not. Unfortunately, current techniques cannot identify which pre-invasive lesions will lead to recurrent cancer. Although screening tools can detect cancer, they cannot predict cancer recurrences.
The present disclosure provides systems and methods for the prediction and treatment of recurrent cancer in a subject. Provided herein is the analysis of subcellular localization of phosphofructokinase type L (PFKL), phosphofructokinase/fructose-2,6-bisphosphatase type 4 (PFKFB4), and other biomarkers, and correlation thereof to the likelihood of cancer (e.g., DCIS) recurrence.
In some embodiments, the methods comprise determining intracellular localization of at least one biomarker (e.g., PFKL, PKKFB4, pGLUT1, etc.) for cancer recurrence in a sample comprising cancer cells from a subject and predicting cancer recurrence in a subject. In some embodiments, the peripheral intracellular localization of at least one biomarker predicts cancer recurrence. In some embodiments, the methods further comprise a) immunostaining the sample with a primary antibody directed to the biomarker for cancer recurrence and b) imaging the sample. In some embodiments, the primary antibody is detected with a secondary antibody comprising a detectable label. In some embodiments, imaging the sample comprises fluorescence microscopy.
In some embodiments, the biomarker for cancer recurrence is phosphofructokinase type L (PFKL) or phosphofructokinase/fructose-2,6-bisphosphatase type 4 (PFKFB4). In some embodiments, intracellular localization of both PFKL and PKKFB4 is analyzed/monitored. In some embodiments, intracellular localization of one or more other biomarkers is analyzed/monitored along with PFKL and/or PKKFB4, such as glutamate cysteine ligase catalytic domain (GCLC), glutathione synthetase (GS), cystine-glutamate antiporter (xCT), CD44v9, glutamine uptake transporters ASCT2, ATBO+ and LAT1, leucine uptake (LAT1), g-glutamyl transpeptidase (GGT), g-glutamyl cysteine (gGC), glucose transporter 1 (GLUT1), glucose 6-phosphate dehydrogenase (G6PD), transketolase (TKT), transketolase-like protein 1 (TKTLP1), RhoA, RhoA with bound GTP and CD74.
The cancer may be breast cancer, prostate cancer, lung cancer, melanoma, kidney cancer, thyroid cancer, pancreatic cancer, stomach cancer or bladder cancer. In some embodiments, the breast cancer comprises ductal carcinoma in situ of the breast, lobular carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia. In select embodiments, the cancer recurrence is ipsilateral breast cancer recurrence. In select embodiments, the sample comprises a formalin-fixed paraffin-embedded cancer tissue sample or a cancer metastases tissue or cell sample.
In some embodiments, the methods further comprise treating a subject predicted to have cancer recurrence. The treatment may include surgery or administration of inhibitors to enzyme or transporter accumulation at plasma membrane. In some embodiments, the inhibitors to enzyme accumulation at plasma membrane comprise colchicine, taxol, a calmodulin antagonist, a prenylation inhibitor, an anesthetic, or combinations thereof.
Provided herein are methods of preventing cancer recurrence in a subject comprising predicting cancer recurrence by the methods disclosed herein and administering a treatment regimen. The treatment regimen may comprise one or more of surgery; administration of an inhibitor(s) to enzyme or transporter accumulation at plasma membrane; immunotherapy; radiotherapy; and administration of a chemotherapeutic agent(s).
Further disclosed herein a systems for use in predicting cancer recurrence or distinguishing between recurrent and non-recurrent cancer. The systems comprise at least one or all of a primary antibody to a biomarker for cancer recurrence; an imaging instrument; software configured to determine the intracellular location of the biomarker for cancer recurrence and a sample.
The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear; in the event, however of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
As used herein, the terms “administering,” “providing”, and “introducing,” are used interchangeably herein and refer to the placement of therapeutic agents into a subject by a method or route which results in at least partial localization a desired site. The therapeutic agents can be administered by any appropriate route which results in delivery to a desired location in the subject.
“Antibody” and “antibodies,” as used herein, refers to monoclonal antibodies, monospecific antibodies (e.g., which can either be monoclonal, or may also be produced by other means than producing them from a common germ cell), multispecific antibodies, human antibodies, humanized antibodies (fully or partially humanized), animal antibodies such as, but not limited to, a bird (for example, a duck or a goose), a shark, a whale, and a mammal, including a non-primate (for example, a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, etc.) or a non-human primate (for example, a monkey, a chimpanzee, etc.), recombinant antibodies, chimeric antibodies, single-chain Fvs (“scFv”), single chain antibodies, single domain antibodies, Fab fragments, F(ab′) fragments, F(ab′)2 fragments, disulfide-linked Fvs (“sdFv”), and anti-idiotypic (“anti-Id”) antibodies, dual-domain antibodies, dual variable domain (DVD) or triple variable domain (TVD) antibodies (dual-variable domain immunoglobulins and methods for making them are described in Wu, C., et al., Nature Biotechnology, 25(11):1290-1297 (2007) and PCT International Application WO 2001/058956, the contents of each of which are herein incorporated by reference), or domain antibodies (dAbs) (e.g., such as described in Holt et al. (2014) Trends in Biotechnology 21:484-490), and including single domain antibodies sdAbs that are naturally occurring, e.g., as in cartilaginous fishes and camelid, or which are synthetic, e.g., nanobodies, VHH, or other domain structure), and functionally active epitope-binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, namely, molecules that contain an analyte-binding site. Immunoglobulin molecules can be of any type (for example, IgG, IgE, IgM, IgD, IgA, and IgY), class (for example, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).
As used herein, the term “biomarker” refers to a substance, the detection of which indicates a particular disease/condition or risk of acquiring/having a particular disease/condition. In the context of the method described herein, a “biomarker” can be a protein (e.g. an enzyme or transporter) that changes location with a cell as a predictor of cancer recurrence or an indicator of recurrent cancer.
As used herein, the term “chemotherapeutic” or “anti-cancer drug” includes any drug used in cancer treatment or any radiation sensitizing agent. Chemotherapeutics may include alkylating agents (including, but not limited to, cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, nitrosoureas, and temozolomide), anthracyclines (including, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin), cytoskeletal disrupters or taxanes (including, but not limited to, paclitaxel, docetaxel, abraxane, and taxotere), epothilones, histone deacetylase inhibitors (including, but not limited to, vorinostat and romidepsin), topoisomerase inhibitors (including, but not limited to, irinotecan, topotecan, etoposide, teniposide, and tafluposide), kinase inhibitors (including, but not limited to, bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib), nucleotide analogs and precursor analogs (including, but not limited to, azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and tioguanine), peptide antibiotics (including, but not limited to, bleomycin and actinomycin), platinum-based agents (including, but not limited to, carboplatin, cisplatin and oxaliplatin), retinoids (including, but not limited to, tretinoin, alitretinoin, and bexarotene), vinca alkaloids and derivatives (including, but not limited to, vinblastine, vincristine, vindesine, and vinorelbine), or combinations thereof. The chemotherapeutic may in any form necessary for efficacious administration and functionality. “Chemotherapy” designates a therapeutic regimen which includes administration of a “chemotherapeutic” or “anti-cancer drug.”
As used herein, the term “preventing” refers to partially or completely delaying or inhibiting onset of an infection, disease, disorder and/or condition; partially or completely delaying or inhibiting onset of one or more symptoms, features, or clinical manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying or inhibiting onset of one or more symptoms, features, or manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying progression from an infection, a particular disease, disorder and/or condition; and/or decreasing the risk of developing pathology associated with the infection, the disease, disorder, and/or condition. 100% inhibition or elimination of risk is not necessary to achieve “preventing.” As used herein, f the likelihood of a population developing a condition is achieved, then the condition is prevented for an individual within that population.
The terms “sample,” “biological sample,” and “test sample” are used interchangeably herein to refer to any material, biological fluid, tissue, or cell obtained or otherwise derived from an individual. The term sample also includes materials derived from a tissue culture or a cell culture. This includes blood (including whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, and serum), mucosal biopsy tissue and brushed cells, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, lymph fluid, nipple aspirate, bronchial aspirate (e.g., bronchoalveolar lavage), bronchial brushing, synovial fluid, joint aspirate, organ secretions, cells, a cellular extract, and cerebrospinal fluid. This also includes experimentally separated fractions of all of the foregoing. For example, a blood sample can be fractionated into serum, plasma, or into fractions containing particular types of blood cells, such as red blood cells or white blood cells (leukocytes). Any suitable methods for obtaining a sample can be employed; exemplary methods include, e.g., phlebotomy, swab (e.g., buccal swab), and a fine needle aspirate biopsy procedure. Exemplary tissues susceptible to fine needle aspiration include lymph node, lung, lung washes, BAL (bronchoalveolar lavage), thyroid, breast, pancreas, and liver. Samples can also be collected, e.g., by micro dissection (e.g., laser capture micro dissection (LCM) or laser micro dissection (LMD)), bladder wash, smear (e.g., a PAP smear), or ductal lavage. A sample obtained or derived from an individual includes any such sample that has been processed in any suitable manner after being obtained from the individual. It will be appreciated that obtaining a biological sample from a subject may comprise extracting the sample directly from the subject or receiving the sample from a third party. In the context of the method described herein, the sample comprises cells.
A “subject” or “patient” may be human or non-human and may include, for example, animal strains or species used as “model systems” for research purposes, such a mouse model as described herein. Likewise, patient may include either adults or juveniles (e.g., children). Moreover, patient may mean any living organism, preferably a mammal (e.g., human or non-human) that may benefit from the administration of compositions contemplated herein. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In one embodiment of the methods and compositions provided herein, the mammal is a human.
As used herein, “treat,” “treating” and the like means a slowing, stopping or reversing of progression of a disease or disorder. The term also means a reversing of the progression of such a disease or disorder. As such, “treating” means an application or administration of the methods or agents described herein to a subject, where the subject has a disease or a symptom of a disease, where the purpose is to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or symptoms of the disease.
Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
The present disclosure provides systems and methods for the prediction and treatment of recurrent cancer in a subject. Provided herein is the analysis of subcellular localization of phosphofructokinase type L (PFKL), phosphofructokinase/fructose-2,6-bisphosphatase type 4 (PFKFB4), and other biomarkers, and correlation thereof to the likelihood of cancer (e.g., DCIS) recurrence.
Experiments conducted during development of embodiments herein using ductal carcinoma in situ (DCIS) of the breast as a framework to better understand the mechanism of cancer recurrences using patient outcomes as the physiological observable. Conventional pathology slides were labeled with antiphosphofructokinase type L (PFKL) and anti-phosphofructokinase/fructose-2,6-bisphosphatase type 4 (PFKFB4) reagents. PFKL and PFKFB4 were found in ductal epithelial cell nucleoli from DCIS samples of women who did not experience a cancer recurrence. In contrast, PFKL and PFKFB4 may be found near the plasma membrane in samples from patients who will develop recurrent cancer. Using machine learning to predict patient outcomes, holdout studies of individual patient micrographs for the three biomarkers PFKL, PFKFB4, and phosphorylated GLUT1 demonstrated 38.6% true negatives, 49.5% true positives, 11.9% false positives and 0% false negatives (N=101). A sub-population of recurrent samples demonstrated PFKL, PFKFB4, and phosphorylated glucose transporter 1 accumulation at the apical surface of epithelial cells, suggesting that carbohydrates can be harvested from the ducts' luminal spaces as an energy source. These experiments indicate that PFK isotype patterns are metabolic switches representing key mechanistic steps of recurrences. Furthermore, PFK enzyme patterns within epithelial cells contribute to an accurate diagnostic test to classify DCIS patients as high or low recurrence risk.
The robust diagnostic ability of enzyme and transporter trafficking to the plasma membrane of DCIS samples prior to breast cancer recurrences provides an accurate diagnostic test to identify at risk DCIS patients. In some embodiments, the methods herein prevent the over-diagnosis of life-threatening cancer; thereby reducing the need for unnecessary treatments.
Some embodiments herein employ machine learning to improve outcome predictions. Some embodiments employ diagnostic machine vision applications within imaging software such that outcomes are calculated/evaluated at the time of initial diagnosis.
The present disclosure provides methods of predicting cancer recurrence in a subject, methods of preventing cancer recurrence in a subject and methods for distinguishing recurrent from non-recurrent cancer. The methods comprise determining intracellular localization of at least one biomarker (e.g., PFKL, PKKFB4, pGLUT1, etc.) for cancer recurrence in a sample from a subject comprising cancer cells. The methods may further comprise predicting cancer recurrence in the subject. In some embodiments, peripheral intracellular localization of at least one biomarker (e.g., PFKL, PKKFB4, pGLUT1, etc.) predicts cancer recurrence or indicates recurrent cancer. A biomarker (e.g., PFKL, PKKFB4, pGLUT1, etc.) has peripheral intracellular localization when it is not centrally or homogeneously located throughout the cell but rather the localization is towards the edges of the cell near the cell membrane.
The intracellular localization may be determined using any histochemical analysis well known in the art. Histochemical analyses include but are not limited to, immunohistochemistry or immunostaining, cytochemistry, histopathology, in situ hybridization, and the use of molecular probes. Texts illustrating histochemical techniques include “Histochemical and Immunochemical Techniques: Application to pharmacology and toxicology,” (1991) Bach, P. and Baker, J., eds., Chapman & Hall, New York, N.Y. pp 1-9, and in “Stains and Cytochemical Methods,” (1993) M. A. Hayat, ed., Plenum Press, New York, N.Y., incorporated herein by reference.
In some embodiments, determining intracellular localization of at least one biomarker for cancer recurrence comprises: a) immunostaining the sample with a primary antibody directed to at least one biomarker for cancer recurrence; and b) imaging the sample.
Detecting the primary antibody may be done directly or indirectly. In some embodiments, the primary antibody is detected with a secondary antibody configured to noncovalently attached to the primary antibody. Examples of secondary antibody include anti-mouse, rabbit, bovine, goat, sheep, dog and chicken antibodies. The secondary antibody comprises a detectable label, e.g. a fluorescent tag, a luminescent tag, an enzyme, an enzyme substrate, or a radiolabel covalently attached to the antibody. In some embodiments, the primary antibody is detected by a non-antibody binding protein such as protein G, protein A, protein L, and a lectin which may contain a detectable label as described for the secondary antibody. In some embodiments, primary or secondary antibodies may be suitable antibody fragments (e.g., Fab, Fab′, F(ab′)2, Fv, scFv, Fd, diabodies, etc.) or other antigen binding elements (e.g., DARPin, anticalin, nanobody, aptamer, affimer, etc.). Alternatively, the primary antibody may contain a detectable label, as described above, or may be modified with another type of label (e.g. biotin) that binds or interacts with a labeled or non-labeled non-antibody binding partner (e.g. streptavidin).
The type of imaging will be dictated by the detectable labels employed. In exemplary embodiments, a secondary antibody is fluorescently labeled and the imaging comprises fluorescence microscopy. In some embodiments, the secondary antibody comprises an enzyme (e.g. peroxidase or alkaline phosphatase) that produces colored products detectable by light microscopy. In some embodiments, the secondary antibody comprises a radioactive label which can be visualized by autoradiography.
The method may further comprise immunostaining for organelles and other cellular structures, e.g., nuclei and cell membranes, using known methods in the art.
In particular embodiments, the intracellular localization of one or both of PFKL and PKKFB4 are analyzed/quantitated/monitored in cell(s). In some embodiments, the intracellular localization of one or more additional biomarkers are also analyzed/quantitated/monitored in cell(s), such as enzymes and transporters involved in the glutathione cycle including, but not limited to, glutamate cysteine ligase catalytic domain (GCLC), glutathione synthetase (GS), cystine-glutamate antiporter (xCT), CD44v9, glutamine uptake transporters ASCT2, ATBO+ and LAT1, leucine uptake (LAT1), gamma-glutamyl transpeptidase (GGT), gamma-glutamyl cysteine (gGC), glucose transporter 1 (GLUT1), glucose 6-phosphate dehydrogenase (G6PD), transketolase (TKT), transketolase-like protein 1 (TKTLP1), RhoA, RhoA with bound GTP and CD74. In some embodiments, peripheral intracellular localization of the biomarkers predicts cancer recurrence or indicates recurrent cancer.
The cancer may be a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma. The cancer may be a cancer of the bladder, blood, bone, brain, breast, cervix, colon/rectum, endometrium, head and neck, kidney, liver, lung, muscle tissue, ovary, pancreas, prostate, skin, spleen, stomach, testicle, thyroid or uterus. In some embodiments, the cancer is selected from breast cancer, prostate cancer, lung cancer, melanoma, kidney cancer, thyroid cancer, pancreatic cancer, stomach cancer or bladder cancer. The breast cancer may comprise ductal carcinoma in situ of the breast (DICS), lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH), or atypical lobular hyperplasia (ALH). In some embodiments, the cancer recurrence is ipsilateral breast cancer recurrence.
The sample may be any sample which comprises cancer cells, such as a sample from a subject, such as a cancer biopsy or other conventional pathology samples. In some embodiments, the sample comprises a formalin-fixed paraffin-embedded cancer tissue sample or a cancer metastases tissue or cell sample.
The methods may further comprise treating a subject predicted to have cancer recurrence. The treatment or therapeutic regimen may include, but is not limited to, surgery, administration of an inhibitor of enzyme accumulation at the plasma membrane immunotherapy, radiotherapy, administration of a chemotherapeutic agent. In some embodiments, the treatment or therapeutic regimen comprises surgery. In some embodiments, the treatment or therapeutic regimen comprises administration of inhibitors to enzyme or transporter accumulation at plasma membrane. Inhibitors to enzyme accumulation at plasma membrane include, but are not limited to, colchicine, taxol, calmodulin antagonists, anesthetics (e.g. local anesthetics—see Schwartz D, et al, Mol Genet Metab. 2000; 69(2):159-164, incorporated herein by reference in its entirety) and prenylation inhibitors. In some embodiments, the treatment regimen comprises one or more of surgery; administration of inhibitors to enzyme accumulation at plasma membrane; immunotherapy; radiotherapy; and administration of a chemotherapeutic agent.
In some embodiments, a subject predicted to have cancer recurrence is treated with one or more of a chemotherapeutic, immunotherapeutic, radiation, surgery, etc.
In some embodiments, a subject predicted to have cancer recurrence is treated with a suitable chemotherapeutic. In some embodiments, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, protein-protein interaction inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens. Non-limiting examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules such as Gleevec® (Imatinib Mesylate), Velcade® (bortezomib), Casodex (bicalutamide), Iressa® (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, Casodex™, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxanes, e.g., paclitaxel (TAXOL™, Bristol-Myers Squibb Oncology, Princeton, N.J.) and docetaxel (TAXOTERE™, Rhone-Poulenc Rorer, Antony, France); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included as suitable chemotherapeutic cell conditioners are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, (Nolvadex™), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin-11 (CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO). Where desired, a subject it treated with one or more commonly prescribed anti-cancer drugs such as Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, ABVD, AVICINE, Abagovomab, Acridine carboxamide, Adecatumumab, 17-N-Allylamino-17-demethoxygeldanamycin, Alpharadin, Alvocidib, 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide, Anthracenedione, Anti-CD22 immunotoxins, Antineoplastic, Antitumorigenic herbs, Apaziquone, Atiprimod, Azathioprine, Belotecan, Bendamustine, BIBW 2992, Biricodar, Brostallicin, Bryostatin, Buthionine sulfoximine, CBV (chemotherapy), Calyculin, cell-cycle nonspecific antineoplastic agents, Dichloroacetic acid, Discodermolide, Elsamitrucin, Enocitabine, Epothilone, Eribulin, Everolimus, Exatecan, Exisulind, Ferruginol, Forodesine, Fosfestrol, ICE chemotherapy regimen, IT-101, Imexon, Imiquimod, Indolocarbazole, Irofulven, Laniquidar, Larotaxel, Lenalidomide, Lucanthone, Lurtotecan, Mafosfamide, Mitozolomide, Nafoxidine, Nedaplatin, Olaparib, Ortataxel, PAC-1, Pawpaw, Pixantrone, Proteasome inhibitor, Rebeccamycin, Resiquimod, Rubitecan, SN-38, Salinosporamide A, Sapacitabine, Stanford V, Swainsonine, Talaporfin, Tariquidar, Tegafur-uracil, Temodar, Tesetaxel, Triplatin tetranitrate, Tris(2-chloroethyl)amine, Troxacitabine, Uramustine, Vadimezan, Vinflunine, ZD6126 or Zosuquidar.
In some embodiments, a subject predicted to have cancer recurrence is treated with radiation. In some embodiments, radiation therapy is administered for inhibiting abnormal cell growth or treating a hyperproliferative disorder. Techniques for administering radiation therapy are known in the art. Radiation therapy can be administered through one of several methods, or a combination of methods, including without limitation external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy. The term “brachytherapy,” as used herein, refers to radiation therapy delivered by a spatially confined radioactive material inserted into the body at or near a tumor or other proliferative tissue disease site. The term is intended without limitation to include exposure to radioactive isotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioactive isotopes of Lu). Suitable radiation sources for use as a cell conditioner of the present invention include both solids and liquids. By way of non-limiting example, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The radioactive material can also be a fluid made from any solution of radionuclide(s), e.g., a solution of 1-125 or 1-131, or a radioactive fluid can be produced using a slurry of a suitable fluid containing small particles of solid radionuclides, such as Au-198, Y-90. Moreover, the radionuclide(s) can be embodied in a gel or radioactive micro spheres.
In some embodiments, a subject is treated with an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, antiproliferative agents, glycolysis inhibitors, or autophagy inhibitors.
Anti-angiogenesis agents may be selected from agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors. Anti-angiogenesis agents include, for example, rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published Oct. 24, 1996), WO 96/27583 (published Mar. 7, 1996), European Patent Application No. 97304971.1 (filed Jul. 8, 1997), European Patent Application No. 99308617.2 (filed Oct. 29, 1999), WO 98/07697 (published Feb. 26, 1998), WO 98/03516 (published Jan. 29, 1998), WO 98/34918 (published Aug. 13, 1998), WO 98/34915 (published Aug. 13, 1998), WO 98/33768 (published Aug. 6, 1998), WO 98/30566 (published Jul. 16, 1998), European Patent Publication 606,046 (published Jul. 13, 1994), European Patent Publication 931, 788 (published Jul. 28, 1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published Oct. 21, 1999), WO 99/52889 (published Oct. 21, 1999), WO 99/29667 (published Jun. 17, 1999), PCT International Application No. PCT/IB98/01113 (filed Jul. 21, 1998), European Patent Application No. 99302232.1 (filed Mar. 25, 1999), Great Britain Patent Application No. 9912961.1 (filed Jun. 3, 1999), U.S. Provisional Application No. 60/148,464 (filed Aug. 12, 1999), U.S. Pat. No. 5,863,949 (issued Jan. 26, 1999), U.S. Pat. No. 5,861,510 (issued Jan. 19, 1999), and European Patent Publication 780,386 (published Jun. 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or AMP-9 relative to the other matrix-metalloproteinases (e.g., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific examples of MMP inhibitors useful in the invention are AG-3340, RO 32-3555, and RS 13-0830.
Autophagy inhibitors include, but are not limited to chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil™), bafilomycin A1, 5-amino-4-imidazole carboxamide riboside (AICAR), okadaic acid, autophagy-suppressive algal toxins which inhibit protein phosphatases of type 2A or type 1, analogues of cAMP, and drugs which elevate cAMP levels such as adenosine, LY204002, N6-mercaptopurine riboside, and vinblastine. In addition, antisense or siRNA that inhibits expression of proteins including but not limited to ATG5 (which are implicated in autophagy), may also be used.
Tumor cells exhibiting enzyme and transporter trafficking may have high GSH levels and may be able to resist oxidant-mediated chemotherapy and radiotherapy. It is contemplated that inhibition of enzyme and transporter trafficking to the cell periphery in recurrent disease may cause recurrent cancer cells to assume the metabolic properties of non-recurrent cancer cells. In some embodiments, agents inhibiting enzyme accumulation at the plasma membrane are administered to increase the radiosensitivity and chemosensitivity for redox-active drugs. Drug-mediated detachment of glycolytic enzymes from plasma membranes and cytoskeletons (e.g., colchicine, taxol, calmodulin antagonists) have been reported. In some embodiments, DCIS patients exhibiting RhoA and RhoA(GTP) trafficking benefit from prenylation inhibitors, because RhoA's membrane form can undergo prenylation. Thus, in some embodiments, the treatment regimen comprises co-administration of inhibitors of enzyme and transporter accumulation at the plasma membrane and chemotherapy or radiotherapy. In some embodiments, a prenylation inhibitor is administered before treatment to prevent prenylation. In some embodiments, a prenylation inhibitor is administered after treatment to block further prenylation.
In cases of co-administration or selection of more than one treatment regimen, the different therapeutic regimens may be administered together, separately, or subsequently to each other separated by a period of time. For example, the treatment with inhibitors of enzyme and transporter accumulation at plasma membrane may precede any chemotherapy and radiotherapy by a period of time ranging from 1 day to 60 days or surgery may precede administration of inhibitors to enzyme accumulation at plasma membrane, immunotherapy, radiotherapy, or administration of a chemotherapeutic agent.
In those instances when the subject is not predicted to have recurrent cancer, the subject may be monitored and subsequent analysis may be completed during the course of monitoring.
The present disclosure also provides systems (e.g., reagents, computer software, imaging instruments, etc.) for predicting cancer recurrence or distinguishing between recurrent and non-recurrent cancer. The systems may comprise at least one or all of a sample (e.g., positive and/or negative control samples), a primary antibody to a biomarker for cancer recurrence, an imaging instrument (e.g. fluorescence or brightfield microscope), and software configured to determine the intracellular location of the biomarker for cancer recurrence. The description of a sample, biomarkers for cancer recurrence and imaging techniques described elsewhere herein are also applicable to the disclosed system.
The software may be supplied with the systems in any electronic form such as a computer readable device, an internet download, or a web-based portal. The software may be integrated with the imaging instrument to not only determine the intracellular location of the biomarker for cancer recurrence but also predict cancer recurrence. The software may allow a user to view results in real-time, review results of previous samples, and view reports.
The systems can also comprise instructions for using the components of the systems. The instructions are relevant materials or methodologies pertaining to the systems. The materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the systems, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the systems or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
It is understood that the disclosed systems can be employed in connection with the disclosed methods.
Cell metabolism plays an important role in determining cell fate (Refs. 32, 41, 54; incorporated by reference in their entireties). For example, aerobic glycolysis—the catabolism of glucose to lactate in the presence of oxygen—is important in developmental biology, endothelial cell function and adaptive immunity (Refs. 13, 32, 39, 41, 54; incorporated by reference in their entireties). Aerobic glycolysis is also a hallmark of aggressive cancer, and is known as the Warburg effect (Ref. 57; incorporated by reference in its entirety). Cancers have various levels of aggressiveness (Refs. 18, 22, 37; incorporated by reference in their entireties). For example, carcinomas in situ of the thyroid rarely become invasive (Ref. 20; incorporated by reference in its entirety) whereas carcinomas in situ of the bladder frequently recur (Ref. 38; incorporated by reference in its entirety). Several studies have shown that ductal carcinoma in situ of the breast is heterogeneous, and can be indolent or aggressive in nature (Refs. 18, 22, 37; incorporated by reference in its entirety). Experiments were conducted during development of embodiments herein to demonstrate that non-recurrent and recurrent forms of cancer are due to differences in metabolic programming.
Metabolic programming and tumor cell aggressiveness depend upon glucose transport (Ref. 1). Using DCIS as a model system, experiments have demonstrated that accumulation of phospho-Ser226-GLUT1 near epithelial cell surfaces of cribriform, comedo, papillary, and micropapillary DCIS lesions predicts breast cancer recurrences (Ref. 31; incorporated by reference in its entirety). As breast tissue utilizes facilitated diffusion for glucose uptake (Ref. 65; incorporated by reference in its entirety), glucose transport across the basolateral epithelial surface occurs when the glucose concentration in the tumor interstitial fluid (TIF) is greater than its intracellular level. As TIF glucose levels are reduced compared to normal interstitial fluid (Ref. 25; incorporated by reference in its entirety), intracellular glucose must be rapidly metabolized to maintain a glucose gradient and enable net glucose uptake. Glycolytic rates are regulated by four flux-controlling steps (Ref. 53; incorporated by reference in its entirety). Phosphofructokinases type 1 (PFKT), which includes PFKL, PFKM, and PFKP, catalyze a flux controlling step by converting F6P to F(1, 6)BP (
In addition to biochemical factors, enzyme activity is also influenced by physical properties such as environment, binding partners, and clustering. Factors such as pH, potassium concentration, and redox conditions may impact enzyme activity (Ref. 44; incorporated by reference in its entirety). Because enzyme clustering reduces the distances between consecutive steps in a biochemical pathway, it accelerates product formation (Ref. 7, 11, 50; incorporated by reference in their entireties). In addition to reducing the time between consecutive enzymatic steps, enzyme proximity improves product formation because insoluble or reactive intermediates and those intermediates intersecting other pathways may not exhibit product formation in solution. Biological strategies to regulate enzyme location include aggregation, oligomerization, and concentration within organelles or along membranes. PFKL locations include: plasma membranes, microfilaments, linear polymers, cytoplasmic monomers and clumps, intracellular membranes, and nucleoli (
When studying the localization of PFKL and PFKFB4, the markers could be present in multiple assembly states at various locations; it is impossible to score all of the variables by hand. Machine learning, by contrast, uses algorithms to solve classification problems by pattern recognition. Experiments were conducted during development of embodiments herein to using machine learning to predict patient outcomes based upon PFKL and PFKFB4 labeling patterns. A previous study of phospho-GLUT1-labeled tissue samples could not accurately predict patient outcomes using images of solid DCIS lesions (Ref. 31; incorporated by reference in its entirety). However, experiments conducted during development of embodiments herein demonstrated that patients exhibiting breast cancer recurrences release PFKFB4 and PFKL from epithelial cell nucleoli, which then localize to the cell periphery. Images of PFKL, PFKFB4, and phospho-GLUT1 labeling in combination with machine learning accurately predicts 10-year patient outcomes of all DCIS samples. This demonstrates that spatial changes in PFKL, PFKFB4, and phospho-GLUT1 distributions: participate in cancer recurrences, and provide a prognostic test for identifying patients at high and low risk for cancer recurrences.
DCIS patient samples. DCIS samples were studied from 101 women (51 non-recurrent, 50 recurrent) who were followed for at least 10 years. For all DCIS samples, no evidence of lymph node involvement was noted. No evidence of invasive cancer was present. Tissue samples were from partial or total mastectomies of women aged 37-80 years after informed consent was obtained. Patients had no previous or concurrent cancer. FFPE pathology samples were obtained from the St. Louis Breast Tissue Registry (St. Louis, MO) and Beaumont Hospital (Royal Oak, MI). This blinded tissue sourcing strategy was used to ensure that laboratory personnel did not have access to electronic medical records of patients whose samples were under study. The use of human material was in accordance with the Declaration of Helsinki on the use of material in scientific research. All experiments were approved by the University of Michigan IRB (number HUM000044189).
Metastatic breast cancer and normal adjacent tissue samples. Samples of breast cancer metastases were obtained from the NDRI (National Disease Research Interchange; Philadelphia, PA). Patients were 59-75 years of age. The primary tumors were characterized as: invasive mammary carcinoma lobular type, infiltrating ductal carcinoma, and inflammatory breast cancer (N=5). Metastasis to the omentum was found to best illustrate protein localization within metastatic cells. Normal adjacent tissue (NAT) was acquired from NDRI (N=3). These samples were from patients aged 47-72 years who were diagnosed with invasive ductal carcinoma or DCIS.
Immunofluorescence of tissue sections. FFPE samples were cut into 5 μm thick sections. Sections were de-paraffinized and re-hydrated by sequential incubation in a graded ethanol series. After rehydration in PBS with 0.02% Triton X-100 (Thermo-Fisher Sci.), sections were subjected to heat-mediated antigen retrieval in 10 mM citric acid buffer, pH 6.0. Sections were blocked using a blocking solution (10% dried milk in PBS and/or 1% BSA in Tris-buffered saline plus 0.10% Tween-20) for 2 hr. at room temperature. After blocking procedures, sections were incubated with antibody (Table 1) diluted in 1% BSA in PBS overnight at 4° C. After incubation, the sections were washed with PBS. Finally, the sections were incubated with a fluorescent secondary antibody for 1 hr., washed with PBS, and then mounted in Prolong Diamond Antifade medium (Thermo-Fisher Sci., Waltham, MA).
Imaging. Fluorescence microscopy was performed (Refs. 14, 15; incorporated by reference in their entireties) using a Nikon TE2000-U inverted microscope (Nikon, Melville, NY) with a 20× (0.55NA) objective, 1.5× optivar and a back-illuminated Andor iXon electron-multiplying charge-coupled device (EMCCD) camera (Model DV-888; Andor Technology, Belfast, Northern Ireland). Images were captured and processed with Metamorph software (Molecular Devices, Downingtown, PA). To reduce shot noise, each micrograph was an average of 10-15 images, with each image acquired for 0.2 sec. To reduce read noise, the EMCCD chip was cooled to −95° C. Typical camera settings were: multiplication gain, 100; vertical shift speed, 3.04 msec./pixel and 14-bit digitization at 10 MHz. Micrographs were evaluated and auto-scaled using ImageJ software.
Statistical analysis of categorical data. The statistical significance of comparisons of biomarker locations was assessed using contingency tables. Two-by-two contingency tables were constructed using the categorical variables of peripheral or non-peripheral staining and patient outcomes. Tests were performed with the “N−1” chi-squared test (Ref. 10; incorporated by reference in its entirety).
Computed outcome prediction. As the frequency of cancer promoting cells is not known in DCIS samples from patients reporting recurrences, multiple low power micrographs were obtained of recurrent tissue samples. Each micrograph was evaluated for recurrent/non-recurrent predicted outcomes. To estimate the number of micrographs necessary for a correct prediction, 29 consecutive patients reporting a recurrence were assessed. For each of the patients, the number of micrographs required to reach the first micrograph yielding the anticipated recurrence prediction was determined. The data are plotted in
The Custom Vision application of Microsoft's (Redmond, WA) Azure Cognitive Services platform was used for machine outcome predictions. Custom Vision is a state-of-the-art computer vision application. This software tool was deployed as a multiclass (tags: recurrent or non-recurrent) and general domain problem.
The computer was trained with micrographs of PFKL and PFKFB4. Machine training was based on tissues exhibiting peripheral or non-peripheral labeling patterns. This approach minimized the introduction of confounding errors by excluding known false negatives and apparent false positives (recurrence-free patients with peripheral protein labeling) from the training dataset. Micrographs categorized as indeterminant, those with poor focus, and those containing artifacts such as tissue section folds, were not used for training. Limited dataset size is a common problem in medical machine vision applications. To deflect this issue, image augmentation was used (Ref. 51; incorporated by reference in its entirety’). Image mirroring was used to increase the dataset's size. The performance of the computer model was assessed by calculating precision and recall. The precision (or positive predictive value) is:
where TP=true positives and FP=false positives. The recall is defined as:
where FN=false negatives. Data were evaluated using precision-recall curves, which plot these variables across many threshold values. Precision-recall curves are much less sensitive to differences in the numbers of patients in each group than receiver operating characteristic plots (Ref. 49; incorporated by reference in its entirety). The cut-point was typically used at a threshold of 50%. The probability of outcome for each micrograph undergoing computer-assisted diagnosis as recurrent or non-recurrent was generally 99.9 or 100%.
Experiments were conducted during development of embodiments herein to compare PFK labeling patterns of tissue samples from DCIS patients who did not experience a cancer recurrence to those who did experience a recurrence. Phospho-Ser226-GLUT1 accumulates at the periphery of epithelial cells within cribriform, comedo, papillary, and micropapillary DCIS lesions from patients who will experience a recurrence (Ref. 31; incorporated by reference in its entirety). Phosphorylation of Ser226 increases GLUT1's Vmax (Ref. 33; incorporated by reference in its entirety). GLUT1 facilitates glucose movement down its concentration gradient, and intracellular glucose breakdown is necessary to maintain an inward glucose flux. As F(1, 6)BP formation is a flux-controlling step of glycolysis,
To test whether intracellular PFK isotype trafficking accompanies cancer recurrences, experiments were conducted during development of embodiments herein to study the spatial features of PFKs using a panel of monoclonal antibodies (Table 1).
The properties of PFKL and PFKFB4 was evaluated in DCIS samples of patients who will exhibit a cancer recurrence. For DCIS patients experiencing cancer recurrences, PFKL and PFKFB4 were generally not found in the nucleus, but were localized to the cell periphery. The examples of
The peripheral or non-peripheral distributions of PFKL and PFKFB4 for each DCIS patient were scored, then assembled into Table 2. To document the statistical significance of these observations, the intracellular locations of PFKL and, independently, PFKFB4 were treated as categorical variables (peripheral or non-peripheral) in statistical analyses. A single micrograph of a patient exhibiting peripheral biomarker labeling was sufficient to define that patient as exhibiting peripheral labeling. Although the peripheral accumulation of PFKL or PFKFB4 could vary from patient-to-patient, both contingency tables yielded P<0.0001. It should be noted that five cases of contralateral recurrences and one unreadable sample were not included in these calculations. These population findings suggest that the relocation of PFKs within pre-invasive epithelial cells is highly significant.
1The terms precision and recall are parameters used for classification models in machine learning. The precision and recall are defined in the Methods.
2N is the number of micrographs.
3A total of 78 patients were used to construct this model.
Heterogeneity of PFKL and PFKFB4 disposition in samples from recurrent patients To further illustrate the heterogeneity of labeling patterns for samples from patients exhibiting recurrences,
Although peripheral labeling is typically uniform, specific biomarker clustering at the apical surface are observed. For example,
PFKL and PFKFB4 labeling patterns of samples of breast cancer metastases were examined.
To determine if these markers could predict individual patient outcomes, machine learning tests were performed. Machine learning was used to make outcome predictions because it provides results superior to visual observations (Ref. 31; incorporated by reference in its entirety), due to its ability to identify multiple predictive image elements. Computational models were developed to predict patient outcomes using PFK labeling patterns of patients in the recurrent or non-recurrent classes on the Azure cloud platform. As all patients had partial or full mastectomies, it is impossible to know if the original lesion would have led to cancer. Therefore, machine training was performed as previously described using (peripheral=recurrence and not peripheral=no recurrence) for image selection while excluding micrographs inconsistent with this standard (Ref. 31; incorporated by reference in its entirety). Optimal findings were obtained when the computer was simultaneously trained using images of PFKL and PFKFB4-labeled tissue sections, presumably due to the increase in sample size and similarity of spatial changes. Cross-validation tests of the dataset yielded average performances of 95.8% for recurrent cancers and 92.8% for non-recurrent cancers. The precision and recall of the PFKL/PFKFB4 computational model are plotted as a function of threshold in
Using DCIS lesions of all morphologies, the PFKL and PFKFB4 computer outcome predictions were correct in 92% of the cases, with 2% false positives and 5% false negatives. Using data concerning phospho-GLUT1 accumulation in the plasma membrane's vicinity for all DCIS morphologies, some of which were recently reported (Ref. 31; incorporated by reference in its entirety), it was found that the outcomes were correct in 80% of the cases, with 11% false positives and 9% false negatives. The machine test correctly identified 88.1% of the cases, with 11.9% false positives and 0% false negatives for our study population (
Using normal adjacent tissue (NAT) of breast cancer patients (DCIS and IDC), tissue sections were stained with anti-phospho-Ser226-GLUT1, anti-PFKL and anti-PFKFB4.
The following references, some of which are also cited above by number, are herein incorporated by reference in their entireties.
This application claims the benefit of U.S. Provisional Patent Application No. 63/216,362, filed on Jun. 29, 2021, which is incorporated by reference herein.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/035342 | 6/28/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63216362 | Jun 2021 | US |
